Voglibose MCQs With Answer

Voglibose MCQs With Answer

by

Voglibose MCQs With Answer

Voglibose is an oral alpha-glucosidase inhibitor used in type 2 diabetes to blunt postprandial glucose excursions by delaying carbohydrate digestion and absorption. This focused collection of Voglibose MCQs with answers is tailored for B.Pharm students and emphasizes mechanism of action, pharmacokinetics, dosing strategies, adverse effects, contraindications, drug interactions, and patient counseling. Questions explore practical clinical scenarios, biochemical targets, management of hypoglycemia when combined with other agents, and use in special populations. These MCQs go beyond memorization to test application and problem-solving skills needed for pharmacology exams and clinical practice. Now let’s test your knowledge with 30 MCQs on this topic.

Q1. Which is the primary mechanism of action of voglibose?

  • Stimulates pancreatic insulin secretion
  • Inhibits renal glucose reabsorption
  • Inhibits intestinal alpha-glucosidase enzymes
  • Enhances peripheral insulin sensitivity

Correct Answer: Inhibits intestinal alpha-glucosidase enzymes

Q2. Voglibose is primarily indicated for which condition?

  • Type 1 diabetes mellitus
  • Type 2 diabetes mellitus with postprandial hyperglycemia
  • Diabetic ketoacidosis
  • Gestational diabetes as first-line therapy

Correct Answer: Type 2 diabetes mellitus with postprandial hyperglycemia

Q3. When should voglibose be administered for optimal effect?

  • With the first bite of a meal (before meals)
  • Immediately after meals
  • Only at bedtime
  • Once weekly regardless of meals

Correct Answer: With the first bite of a meal (before meals)

Q4. Which adverse effect is most commonly associated with voglibose?

  • Hypoglycemia as monotherapy
  • Gastrointestinal effects such as flatulence and diarrhea
  • Severe hepatotoxicity
  • Weight gain

Correct Answer: Gastrointestinal effects such as flatulence and diarrhea

Q5. If a patient on voglibose develops hypoglycemia while also taking a sulfonylurea, which oral sugar is preferred to treat the episode?

  • Sucrose (table sugar)
  • Glucose (oral glucose tablets or gel)
  • Fructose-containing fruit juice
  • Lactose-containing milk

Correct Answer: Glucose (oral glucose tablets or gel)

Q6. Voglibose is contraindicated in which of the following conditions?

  • Hypertension
  • Inflammatory bowel disease or malabsorption syndromes
  • Stable coronary artery disease
  • Controlled hypothyroidism

Correct Answer: Inflammatory bowel disease or malabsorption syndromes

Q7. Compared with miglitol and acarbose, voglibose is characterized by which pharmacokinetic feature?

  • High systemic absorption and renal excretion
  • Extensive hepatic metabolism
  • Minimal systemic absorption with predominant local intestinal action
  • Long systemic half-life requiring once-daily dosing

Correct Answer: Minimal systemic absorption with predominant local intestinal action

Q8. The onset of voglibose’s effect on postprandial glucose typically occurs within which timeframe?

  • Within 30 minutes of ingestion
  • Within 1 hour of ingestion
  • After 4–6 hours
  • After 24 hours

Correct Answer: Within 1 hour of ingestion

Q9. How is voglibose primarily eliminated from the body?

  • Metabolized in liver and excreted in urine
  • Extensively metabolized to active metabolites
  • Mostly excreted unchanged in feces due to poor absorption
  • Exhaled as carbon dioxide after metabolic oxidation

Correct Answer: Mostly excreted unchanged in feces due to poor absorption

Q10. A common oral dosing regimen for voglibose in adults is:

  • 0.2 mg once daily
  • 0.2 mg three times daily before meals
  • 5 mg twice daily
  • 50 mg once weekly

Correct Answer: 0.2 mg three times daily before meals

Q11. Combining voglibose with sulfonylureas increases the risk of:

  • Renal failure
  • Severe hepatotoxicity
  • Hypoglycemia
  • Hyperkalemia

Correct Answer: Hypoglycemia

Q12. Typical reduction in HbA1c achieved by voglibose monotherapy is approximately:

  • 0.1–0.2%.
  • 0.5–1.0%.
  • 2–3%.
  • More than 4%.

Correct Answer: 0.5–1.0%.

Q13. Voglibose inhibits the breakdown of which dietary carbohydrates?

  • Monosaccharides only
  • Disaccharides and oligosaccharides at the intestinal brush border
  • Proteins and peptides
  • Lipids and triglycerides

Correct Answer: Disaccharides and oligosaccharides at the intestinal brush border

Q14. The recommended stance on voglibose use in pregnancy is:

  • First-line therapy for gestational diabetes
  • Contraindicated in all pregnant women
  • Use with caution or avoid due to limited safety data
  • Safe and recommended in the first trimester only

Correct Answer: Use with caution or avoid due to limited safety data

Q15. Which parameter best reflects the therapeutic effect of voglibose during monitoring?

  • Fasting plasma glucose only
  • Postprandial blood glucose and 2-hour post-meal glucose
  • Serum potassium
  • Creatine kinase levels

Correct Answer: Postprandial blood glucose and 2-hour post-meal glucose

Q16. Voglibose is most suitable for patients who have which glycemic pattern?

  • Predominant nocturnal hypoglycemia
  • Marked postprandial glucose spikes with relatively controlled fasting glucose
  • Severe fasting hyperglycemia only
  • Type 1 diabetes requiring insulin

Correct Answer: Marked postprandial glucose spikes with relatively controlled fasting glucose

Q17. To which pharmacological class does voglibose belong?

  • Biguanides
  • Sulfonylureas
  • Alpha-glucosidase inhibitors
  • DPP-4 inhibitors

Correct Answer: Alpha-glucosidase inhibitors

Q18. What is the typical effect of voglibose on body weight?

  • Significant weight gain
  • Significant weight loss
  • Weight neutral or minimal effect
  • Causes edema and fluid retention

Correct Answer: Weight neutral or minimal effect

Q19. One clinical advantage of voglibose over systemically absorbed oral agents is:

  • Higher risk of systemic hypoglycemia
  • Lower systemic adverse effects due to minimal absorption
  • Requires renal dose adjustment in all patients
  • Causes significant central nervous system side effects

Correct Answer: Lower systemic adverse effects due to minimal absorption

Q20. What is the recommended dosing frequency for voglibose in relation to meals?

  • Once daily at bedtime
  • Twice daily irrespective of meals
  • Three times daily before each meal
  • Every 48 hours

Correct Answer: Three times daily before each meal

Q21. Is dose adjustment of voglibose usually required in renal impairment?

  • Yes, reduce dose significantly in mild renal impairment
  • Yes, contraindicated in any renal impairment
  • No clear dose adjustment required due to minimal systemic absorption
  • Yes, double the dose in renal impairment

Correct Answer: No clear dose adjustment required due to minimal systemic absorption

Q22. When used as monotherapy, the risk of hypoglycemia with voglibose is:

  • High and common
  • Moderate and expected
  • Low or rare
  • Immediate and unavoidable

Correct Answer: Low or rare

Q23. Which laboratory test is most appropriate to assess voglibose’s effect during an oral glucose tolerance test (OGTT)?

  • Fasting glucose at 0 minutes only
  • 2-hour post-load glucose
  • Serum insulin at baseline only
  • Serum triglycerides

Correct Answer: 2-hour post-load glucose

Q24. Can voglibose be combined with metformin in clinical practice?

  • No, the combination is contraindicated
  • Yes, combination is used to target different pathophysiologic defects
  • Only with insulin, not with metformin
  • Only in type 1 diabetes

Correct Answer: Yes, combination is used to target different pathophysiologic defects

Q25. Which sugar source should be avoided when treating hypoglycemia in a patient taking voglibose?

  • Oral glucose gel
  • Sucrose (table sugar)
  • Pure dextrose solution
  • Oral glucose tablets

Correct Answer: Sucrose (table sugar)

Q26. The mechanism underlying voglibose-induced flatulence is:

  • Inhibition of gastric acid secretion
  • Fermentation of undigested carbohydrates by colonic bacteria
  • Systemic cholinergic stimulation
  • Increased bile acid secretion

Correct Answer: Fermentation of undigested carbohydrates by colonic bacteria

Q27. Voglibose inhibits which intestinal enzymes specifically?

  • Peptidases and proteases
  • Sucrase and maltase (alpha-glucosidases)
  • Pancreatic lipase
  • Amylase only

Correct Answer: Sucrase and maltase (alpha-glucosidases)

Q28. The principal clinical benefit of voglibose is:

  • Lowering fasting glucose without affecting postprandial levels
  • Reducing postprandial glucose excursions and related metabolic stress
  • Causing rapid weight loss
  • Replacing the need for insulin in type 1 diabetes

Correct Answer: Reducing postprandial glucose excursions and related metabolic stress

Q29. Voglibose is contraindicated in patients with which gastrointestinal condition?

  • Peptic ulcer disease well controlled with PPI
  • Intestinal obstruction
  • Mild gastroesophageal reflux disease
  • Constipation only

Correct Answer: Intestinal obstruction

Q30. If a patient develops severe diarrhea and abdominal pain after starting voglibose, the appropriate immediate action is:

  • Increase the voglibose dose
  • Continue therapy and add a laxative
  • Discontinue voglibose and provide supportive care
  • Switch to sucrose-containing supplements

Correct Answer: Discontinue voglibose and provide supportive care

Leave a Comment